Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Feb;17(2):179–182. doi: 10.1111/j.1365-2125.1984.tb02336.x

Calcium antagonists and endocrine status: lack of effect of oral verapamil on pituitary-testicular and pituitary-thyroid function.

C G Semple, J A Thomson, G H Beastall, A R Lorimer
PMCID: PMC1463315  PMID: 6422973

Abstract

Calcium ions seem to be essential for the release of many hormones. The calcium antagonist verapamil which is used as an anti-arrhythmic and anti-anginal agent has an inhibitory effect on the release of follicle stimulating hormone (FSH), luteinising hormone (LH), and thyrotrophin stimulating hormone (TSH) when given as an intravenous infusion to normal volunteers. As verapamil is usually given orally we studied pituitary-testicular and pituitary-thyroid function before and after completing a 4-week course of oral verapamil. The oral preparation did not have any significant effect on the endocrine parameters studied.

Full text

PDF
179

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbarino A., De Marinis L. Calcium antagonists and hormone release. II. Effects of verapamil on basal, gonadotropin-releasing hormone- and thyrotropin-releasing hormone-induced pituitary hormone release in normal subjects. J Clin Endocrinol Metab. 1980 Oct;51(4):749–753. doi: 10.1210/jcem-51-4-749. [DOI] [PubMed] [Google Scholar]
  2. Charles S., Ketelslegers J. M., Buysschaert M., Lambert A. E. Hyperglycaemic effect of nifedipine. Br Med J (Clin Res Ed) 1981 Jul 4;283(6283):19–20. doi: 10.1136/bmj.283.6283.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cole S. C., Flanagan R. J., Johnston A., Holt D. W. Rapid high-performance liquid chromatographic method for the measurement of verapamil and norverapamil in blood plasma or serum. J Chromatogr. 1981 Nov 20;218:621–629. doi: 10.1016/s0021-9673(00)82087-7. [DOI] [PubMed] [Google Scholar]
  4. De Marinis L., Barbarino A. Calcium antagonists and hormone release. I. Effects of verapamil on insulin release in normal subjects and patients with islet-cell tumor. Metabolism. 1980 Jul;29(7):599–604. doi: 10.1016/0026-0495(80)90103-1. [DOI] [PubMed] [Google Scholar]
  5. Gluskin L. E., Strasberg B., Shah J. H. Verapamil-induced hyperprolactinemia and galactorrhea. Ann Intern Med. 1981 Jul;95(1):66–67. doi: 10.7326/0003-4819-95-1-66. [DOI] [PubMed] [Google Scholar]
  6. Karlsberg R. P. Calcium channel blockers for cardiovascular disorders. Arch Intern Med. 1982 Mar;142(3):452–455. [PubMed] [Google Scholar]
  7. Milligan J. V., Kraicer J., Fawcett C. P., Illner P. Purified growth hormone releasing factor increases 45 Ca uptake into pituitary cells. Can J Physiol Pharmacol. 1972 Jun;50(6):613–617. doi: 10.1139/y72-091. [DOI] [PubMed] [Google Scholar]
  8. Podesta E. J., Milani A., Steffen H., Neher R. Steroidogenic action of calcium ions in isolated adrenocortical cells. Biochem J. 1980 Feb 15;186(2):391–397. doi: 10.1042/bj1860391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Semple C. G., Thomson J. A., Beastall G. H., Lorimer A. R. Oral verapamil does not affect glucose tolerance in non-diabetics. Br J Clin Pharmacol. 1983 May;15(5):570–571. doi: 10.1111/j.1365-2125.1983.tb02094.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Struthers A. D., Millar J. A., Beastall G. H., McIntosh W. B., Reid J. L. Calcium antagonists and hormone release: effect of nifedipine on luteinizing hormone-releasing hormone and thyrotropin-releasing hormone-induced pituitary hormone release. J Clin Endocrinol Metab. 1983 Feb;56(2):401–404. doi: 10.1210/jcem-56-2-401. [DOI] [PubMed] [Google Scholar]
  11. Takahara J., Yunoki S., Yamane Y., Yamauchi J., Yakushiji W., Kageyama N., Fujino K., Ofuji T. Effects of nifedipine on prolactin, growth hormone, and luteinizing hormone release by rat anterior pituitary in vitro. Proc Soc Exp Biol Med. 1979 Oct;162(1):31–33. doi: 10.3181/00379727-162-40612. [DOI] [PubMed] [Google Scholar]
  12. Vale W., Burgus R., Guillemin R. Presence of calcium ions as a requisite for the in vitro stimulation of TSH-release by hypothalamic TRF. Experientia. 1967 Oct 15;23(10):853–855. doi: 10.1007/BF02146887. [DOI] [PubMed] [Google Scholar]
  13. Wakabayashi K., Kamberi I. A., McCann S. M. In vitro response of the rat pituitary to gonadotrophin-releasing factors and to ions. Endocrinology. 1969 Dec;85(6):1046–1056. doi: 10.1210/endo-85-6-1046. [DOI] [PubMed] [Google Scholar]
  14. Woodcock B. G., Hopf R., Kaltenbach M. Verapamil and norverapamil plasma concentrations during long-term therapy in patients with hypertrophic obstructive cardiomyopathy. J Cardiovasc Pharmacol. 1980 Jan-Feb;2(1):17–23. doi: 10.1097/00005344-198001000-00003. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES